Emerging Technology: What’s Real in Energy, Health, Aging?

Emerging technology news can feel like three miracles in a single scroll. A shut-down nuclear plant is coming back to feed AI data centers. An algorithm reads your chest scan before a doctor does. A blood test says your body is younger than your birthday suggests.

Some of that is real. Some of it is a press release wearing a lab coat.

We kept noticing one pattern while reporting this hub. In energy, health and longevity, the part that already works is narrow. The part that gets the headline is the extrapolation. So this guide sorts each emerging technology into proven, early or hype, and it shows the evidence behind every rating.

What counts as emerging technology in 2026?

There’s no official list. Analysts, futurists and investors all draw the line in different places. And honestly, “emerging” sometimes just means “we’re raising money for it.”

We use a narrower, human-centric definition. On this site, emerging technology means tools that are starting to change the grid that powers our machines, the bodies those machines diagnose, and how long those bodies stay healthy. Neurotech and robots sit right alongside, because they touch people directly.

That filter cuts out plenty of shiny gadgets. But it keeps the stuff that will show up on your electricity bill, in your hospital chart, or in your mailbox as a biological age test.

The three-question test for any emerging technology

Before we rate anything, here’s the yardstick. It’s simple on purpose, so you can apply it to any emerging technology pitch you see.

1. Is there a deployed, regulated product? Not a demo. Something a regulator signed off on, or a plant that actually makes power.
2. Has anyone checked it independently? The inventor’s own paper counts for less than an outside study.
3. Does the timeline depend on things nobody has built yet? If the promise needs new reactors, new power lines or new biology, discount it.

Pass all three and a technology is proven. One or two passes makes it early. Zero passes plus a big press tour? That’s hype, at least for now.

For example, FDA-authorized AI in radiology clears the first question easily. Small modular reactors fail the third. Aging clocks sit awkwardly in the middle.

Emerging technology and energy: AI’s power problem

Every emerging technology on this page depends on one input. Electricity.

The International Energy Agency puts global data-center electricity use at about 415 TWh in 2024. Its base case reaches roughly 945 TWh by 2030, according to figures the IAEA cites in its 2026 report on nuclear energy and AI. That’s more than double in six years.

The spending behind that curve is huge. In February 2026, Amazon and Google said they expected to spend up to $200 billion and $185 billion respectively on data centers in the coming year, as the Bulletin of the Atomic Scientists reports.

So where does all that power come from? Big Tech keeps answering “nuclear.” But nuclear supplied only 8.8% of global electricity in 2025, roughly half its share 30 years earlier. Those are the Bulletin’s figures, based on the Energy Institute’s Statistical Review 2026. Wind and solar supplied 19.5%, and large hydro 13.9%.

That gap is why the question here is narrow. Which parts of the nuclear story actually pass the test?

What’s proven: restarting an old reactor

The most concrete deal is the restart of Three Mile Island Unit 1, now called the Crane Clean Energy Center. Microsoft signed a 20-year power purchase agreement for the plant’s 835 MW output. Constellation still targets a 2027 return to service.

The financing exists, too. The project costs about $1.6 billion, and a $1 billion Department of Energy loan closed in November 2025, the Pennsylvania Capital-Star reported.

But “financed” isn’t “running.” In September 2026, the Nuclear Regulatory Commission issued a final environmental assessment that found no significant impact. That clears one hurdle. It doesn’t authorize a restart by itself. Also, one industry tracker notes that grid operator PJM said full transmission upgrades may take until after 2030.

Our verdict: proven as a project, still early as a power source. And it’s one plant.

What’s early: small modular reactors

Small modular reactors, or SMRs, are where headlines get loud and contracts get quiet.

Take Amazon’s SMR deal. The Bulletin points out that it only funds an initial feasibility phase. In return, Amazon gets the right to buy power from the first project: four modules, 320 MW in total. A right to buy isn’t a reactor.

Google’s agreement with Kairos Power covers 500 MW of advanced nuclear by 2035. Yet the announcements say nothing about power-purchase terms, the Bulletin notes.

Then there’s the track record. Bulletin authors Molly Langabeer and M.V. Ramana gather numbers that should cool anyone’s excitement:

• New US nuclear power costs about three times as much per unit as solar or wind.
• In one study of 180 nuclear projects, 175 ran over their initial budgets and timelines.
• Russia’s first KLT-40S SMR took 13 years to build. The plan said three.
• No SMR projects are under construction in the US right now.
• In 2020, the DOE aimed for SMRs running within 5–7 years. By November 2025, TerraPower was promising grid power from its Natrium plant by 2031.
• Natrium’s estimated price is $9.4 billion for 345 MW. NuScale’s Idaho project, at $9.3 billion for 462 MW, died over cost in 2023.

Their core argument is blunt. Nuclear and small reactors can’t meaningfully raise data-center supply soon, especially in the next few years when AI demand grows fastest.

For balance, Forbes’ Ken Silverstein frames it differently. He reports that Big Tech is directly financing nearly 10 GW of nuclear capacity, and he argues the AI boom is making nuclear bankable again. Both things can be true. Money is moving. Concrete isn’t, yet.

The grid problem nobody headlines

Most coverage stops at “AI needs more power.” The IAEA’s 2026 report flags a stranger issue. AI training loads swing hard, and a data center can shed hundreds of megawatts within seconds when a training run finishes.

Swings like that stress grid stability, no matter what kind of plant sits at the other end of the wire. So even a perfect reactor wouldn’t solve everything. Our hunch? The emerging technology that matters most for AI power may turn out to be the unglamorous kind, like smarter ways to manage those swings.

Emerging technology in health: AI that reads scans

Health is where emerging technology has cleared the regulator test most often.

The FDA’s list of AI-enabled medical devices passed 1,600 authorizations as of September 2026. An analysis by Sequenex counted 1,614 entries in the September 4 update. Annual authorizations climbed from 6 in 2015 to 335 in 2025.

Look inside the list, though, and the picture narrows fast:

• About 1,230 entries, roughly 76%, are radiology tools.
• Cardiovascular devices come a distant second, at 154.
• 1,553 devices came through the 510(k) pathway. Only 21 came through premarket approval (PMA).
• As of March 2026, The Medical Futurist found no authorized device that uses generative AI or a large language model.

That last point matters most. The chatbot doctor you keep reading about isn’t on the list. The AI that’s actually in hospitals mostly looks at images. That’s what maturing tech tends to look like: specific, regulated and a little boring.

Why 1,600 approvals isn’t 1,600 proofs

Authorization and proof are different claims. The FDA itself says its list isn’t a comprehensive resource. The Paragon Institute calls it a regulatory snapshot, not a measure of how often tools get used or whether patients do better. Then there’s an April 2026 opinion piece in Clinical Trial Vanguard, which argues that rigorous randomized-trial evidence still trails the authorizations.

So here’s the honest rating. AI image reading is proven in the sense that it’s deployed and regulated. But whether each tool improves patient outcomes is still an open question for many of them.

What about AI-designed drugs and health wearables? We didn’t find vetted numbers strong enough to rate them here, so we won’t pretend. If a headline hands you a precise figure for either, ask where it came from.

Emerging technology and longevity: healthspan vs lifespan

Longevity is the most personal story here. It also has the most money chasing the most uncertainty.

First, a distinction that clears up a lot of confusion. Lifespan is how long you live. Healthspan is how long you live in good health. They aren’t the same, and the gap widened between 2000 and 2019.

WHO data, as summarized by InVivo Biosystems, show global life expectancy rose 6.6 years between 2000 and 2019. Healthy life expectancy rose only 5.4 years. The commonly cited gap between the two sits around nine years. In plain terms, we’re adding years faster than we’re adding good years.

That’s why serious longevity work now targets healthspan, not a bigger number on the birthday cake.

Aging clocks: validated and questioned at once

Biological age clocks are what most people meet first, usually as a mail-in test. Epigenetic clocks estimate how old your body seems from chemical tags on your DNA.

In mid-2026, the field got a validation and a challenge almost back to back. A ScienceDirect editorial by Neil Panchal pulled three papers together.

The good news came from a big head-to-head test. Researchers compared 14 epigenetic clocks across 174 disease outcomes in 18,859 adults from Generation Scotland, with 10 years of follow-up. Newer clocks such as PhenoAge, GrimAge and DunedinPACE accounted for most of the significant links. First-generation clocks like Horvath and Hannum accounted for only about 5%.

Now the catch. Adding a clock to standard risk factors improved 10-year prediction by more than one percentage point in only 32 of 176 significant results. Real, but modest.

A second study followed 699 adults in the InCHIANTI cohort for up to 24 years. Clocks that combined a starting value with the rate of change reached C-statistics of 0.800–0.808 for mortality. That’s solid prediction. However, the rate of change alone didn’t predict death without the baseline. One reading tells you far less than a series.

The third paper, Kriukov and colleagues’ “Do we actually need aging clocks?”, argues that clocks often add little over predicting the outcomes directly.

Panchal’s own conclusion is careful. Clocks are “clinically useful” inside a longitudinal, multimodal setup, he writes, but “transitional” as a standalone paradigm.

One more detail matters. DunedinPACE’s inventor co-authored the validation paper, and the method is licensed to TruDiagnostic, a commercial lab. That doesn’t make the result wrong. It does mean you should want outside replication.

Can an aging clock tell you a treatment works?

This is where marketing runs furthest ahead of science.

A 2026 review by Johnson and Sinclair in Frontiers in Genetics reports that nicotinamide riboside, rapamycin and senolytics showed no detectable effect on next-generation clocks. Plasmapheresis and some other therapies seemed to speed up epigenetic aging instead. The authors also say clocks aren’t yet validated as clinical surrogate endpoints. So a lower clock score can’t stand in for a real health result.

Noise makes it worse. A May 2026 review in Biogerontology notes that some commercial tests report no peer-reviewed validation of the specific product. It also cites Higgins-Chen and colleagues (2022), who reported replicate agreement of about 1.5 years for principal-component clocks. If your test says you got a year younger, that might just be the lab.

Then there’s the deeper problem. A December 2025 Nature Communications analysis found no single clock beat the rest across the board, and most clocks rest on correlation, not causation. A clock can flag risk. It can’t tell you what to change.

Can AI make people live longer?

AI gets pitched as the shortcut. But a review on AI for longevity states plainly that radical longevity, meaning healthy life well beyond a century, isn’t achievable with current technology and current understanding of aging.

So the realistic goal isn’t immortality. It’s shrinking that nine-year gap between living and living well. Frankly, that’s a better goal anyway.

Where neurotech and robots fit

Brain-computer interfaces, neuromodulation wearables, exoskeletons and care robots all belong in an honest map of human-centric emerging technology. They change bodies and minds directly, which is exactly our filter.

We didn’t re-research them for this hub, and we won’t recycle claims without fresh sources. But the same three questions apply. Is there a regulated product or a trial? Who checked the results? Does the promise depend on hardware or surgery that doesn’t exist yet?

Our cluster guides walk through the evidence for each, and that’s where to start before believing a headline.

Where to go next in neurotech and robots

• Brain interfaces. Start with how brain-computer interfaces work for the full pipeline, from the electrode to the decoded command. The rest of our BCI coverage builds on it.
• Exoskeletons. For wearable hardware you can actually buy today, our Hypershell vs Dnsys exoskeleton comparison sets the two side by side and says who each one suits.
• Care robots and humanoids. They share the same basic parts list. Our guide to how humanoid robots work covers the actuators, joints and AI that tie them together.

Read each one with the three questions in your pocket. A trial isn’t a product. A demo video isn’t independent testing. And a robot that needs parts nobody ships yet is a promise, not a plan.

Emerging technology compared: proven, early or hype

Here’s the scorecard for each emerging technology in this hub. Maturity follows our three-question test, and the timelines come from the sources above.

One pattern jumps out. Every proven row is narrow. Every hype row is an extrapolation from a narrow win.

Risks of emerging technology: who pays and who’s left out

Hype isn’t the only danger. Some costs land on people who never signed up for them.

Who pays for the power. If new nuclear electricity costs roughly three times solar or wind, somebody covers the difference. Is it customers, taxpayers backing DOE loans, or the tech companies? The deal announcements rarely say.

Proliferation. A December 2024 Bulletin piece argued that the AI-nuclear excitement barely mentions proliferation or fissile-material risks. More reactors should mean more of that conversation, not less.

Who the science leaves out. Panchal’s editorial flags limits in cohort ancestry and in sex-specific analysis. A clock built mostly from one population could misread another.

Who holds your data. Age tests, health wearables and brain interfaces all collect intimate information. So before you mail off a blood sample, read who keeps it and who they can share it with. For the bigger picture, our explainer on how AI is regulated maps the EU AI Act and the wider global rulebook.

Who profits from the validation. The DunedinPACE licensing arrangement is disclosed. Still, it’s a reminder to ask who benefits when a test gets a glowing review.

How to read the next emerging technology headline

Keep this list handy. It works on energy, health and longevity stories alike.

• “Right to purchase” or “feasibility” means not built. The Bulletin’s warning about SMR deal language fits most big-tech energy announcements.
• Environmental clearance isn’t permission to operate. Crane’s NRC finding shows the gap.
• FDA-authorized isn’t outcome-proven. Ask whether a trial showed patients actually doing better.
• No LLM device had FDA authorization as of March 2026. If an app implies otherwise, check the list yourself.
• A prediction isn’t a cause. Aging clocks correlate with disease, so lowering your score isn’t automatically a treatment.
• One reading is weak. Clocks predicted mortality best when they tracked change over time.
• Ask who funded the validation. Then look for someone who didn’t.

Why this matters

Hype-checking can look like cynicism. It isn’t. The restart at Crane, the radiology tools on the FDA list and the newer aging clocks are genuine progress, and they deserve credit for what they really do.

The trouble starts when a narrow win gets sold as the whole future. A feasibility study becomes “nuclear-powered AI.” A scan reader becomes “the AI doctor.” A correlation becomes “reverse your age.”

That’s also why this page is a hub, not a final word. The numbers move. Crane’s 2027 date could hold or slip. The FDA list grows with each update. Clock researchers keep publishing, sometimes validating and challenging the same tools within a few months. We’ll revisit these ratings as the evidence shifts, and we’ll say so plainly when a verdict flips.

Our bet is simple. The next decade of emerging technology will reward people who ask the boring questions. What’s built? Who checked? What still has to exist first?

So which headline are you least sure about right now? Start there.